ALZHEIMER'S DISEASE & RELATED DEMENTIAS

Understanding the Biochemical Basis of
Alzheimer's Disease

While much attention has focused on amyloid plaques and tau tangles, a deeper understanding of the biochemistry reveals a more fundamental story — one centered on plasmalogens, specialized lipids critical to brain health.

BEYOND AMYLOID

Why the Amyloid Hypothesis Falls Short

Alzheimer’s disease is the most common form of dementia, affecting millions of people worldwide. For decades, the dominant theory has centered on amyloid plaques and tau tangles as the primary drivers of the disease.

Many individuals with extensive amyloid pathology in their brains never develop dementia, and treatments targeting amyloid have largely failed to produce meaningful clinical benefits.

A more fundamental understanding emerges when we examine the cell membranes themselves. The brain is extraordinarily rich in specialized lipids called plasmalogens — particularly ethanolamine plasmalogens. These unique phospholipids constitute approximately 30% of total phospholipids and a remarkable 90% of ethanolamine glycerophospholipids in neuronal cell membranes.

Blood plasmalogen levels Alzheimer's prevalence

Sources: Goodenowe et al., J Lipid Res 2007; Maeba et al., J Atheroscler Thromb 2007; Alzheimer's Association 2025 Facts & Figures. Curves are representative of published trends, not plotted from individual data points.

PLASMALOGEN FUNCTION

The Role of Plasmalogens in Brain Health

Plasmalogens differ from ordinary phospholipids by having a vinyl ether bond at the sn-1 position of the glycerol backbone. This seemingly small chemical difference has profound consequences for brain function.

Antioxidant Protection

The vinyl ether bond acts as a sacrificial antioxidant, protecting other membrane components from oxidative damage.

Membrane Fluidity

Plasmalogens create distinct conformational motifs in membrane bilayers, affecting membrane dynamics essential for normal cell function.

Vesicular Fusion

They facilitate rapid membrane fusion necessary for neurotransmitter release — the chemical signaling between brain cells.

Cholesterol Regulation

Plasmalogens are key regulators of membrane cholesterol levels, influencing amyloid processing and overall membrane health.

DEFICIENCY IN ALZHEIMER'S DISEASE

How Plasmalogen Deficiency Drives Alzheimer's Progression

The evidence linking plasmalogen deficiency to Alzheimer’s is not speculative. It is robust, replicated, and quantifiable. Research has consistently demonstrated that plasmalogen deficiency is present in the brains of Alzheimer’s patients across multiple independent studies:

  • Circulating ethanolamine plasmalogen levels are significantly decreased in serum from clinically and pathologically diagnosed AD subjects at all stages of dementia
  • The severity of plasmalogen decrease correlates with the severity of dementia
  • Low blood plasmalogen levels correlate with low brain plasmalogens, low cognitive scores (MMSE), and high levels of neurofibrillary tangles in the brain
  • Pre-mortem blood plasmalogen deficiency correlated with severity of dementia in post-mortem confirmed Alzheimer’s patients

But correlation, however strong, is not causation. The critical insight comes from understanding the mechanism—the step-by-step biochemical pathway through which plasmalogen deficiency leads to the features we recognize as Alzheimer’s disease. 

THE MECHANISM

The Biochemical Cascade

This cascade reveals why a single lipid deficiency can have such wide-ranging and devastating effects on brain function.

Increased Membrane Cholesterol

Plasmalogen-deficient cells accumulate excess cholesterol in their membranes, disrupting normal lipid organization.

1
Reduced Membrane Fluidity

Elevated cholesterol, combined with reduced plasmalogens, creates rigid, inflexible cell membranes that are unable to support normal function.

2
Impaired Ion Channel Function

Rigid membranes cannot support proper ion channel activity.

3
Disrupted Signal Transduction

Membrane-bound enzymes and diffusion of signaling molecules like nitric oxide are compromised.

4
Reduced Neurotransmitter Release

Vesicular fusion is impaired, leading to decreased acetylcholine release - the cholinergic deficit central to Alzheimer's Disease.

5
Enhanced Amyloid Production

Elevated membrane cholesterol increases Aβ42 production, and plasmalogens directly inhibit gamma-secretase activity involved in APP processing.

6
Neurodegeneration & Cognitive Decline
⚠️
DISCOVERY TIMELINE

Plasmalogens and Alzheimer's Research

1995-2001:
Early Observations
The first hints emerged in the 1990s. Ginsberg et al. (1995) reported disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Han et al. (2001) used electrospray ionization mass spectrometry to molecularly characterize plasmalogen deficiency in early Alzheimer's disease subjects and animal models.
2005:
The Breakthrough Technology
The major breakthrough came with the development of ultra-high-resolution Fourier transform ion cyclotron resonance mass spectrometry (FT-ICR-MS). Dr. Dayan Goodenowe invented a patented technology for non-targeted complex sample analysis that could simultaneously measure thousands of biomarkers from a small blood sample.
His laboratory was the first to identify several novel biochemical biomarkers that are decreased in the blood of individuals with dementia. Subsequently, he identified these biomarkers as plasmalogens. This is how low blood plasmalogen levels in dementia were discovered.
2006-2007:
Patents and Publication
In February 2006, Goodenowe filed a patent application for a method of diagnosing dementia based on plasmalogen deficiency. In February 2007, he filed a patent for the treatment of dementia using plasmalogen precursors, and in 2007, filed a patent on the causal role of plasmalogen deficiency in diseases of aging. The definitive peer-reviewed research article was published in the Journal of Lipid Research in 2007, titled "Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia." This landmark paper, in collaboration with several international scientists and clinicians, confirmed the discoveries and hypothesized that plasmalogen deficiency was a key causal mechanism underlying dementia.
2007-Present:
Independent Confirmation
These findings have been reproduced by independent researchers in multiple clinical trials around the world. Studies in Japanese populations, analysis of the Alzheimer's Disease Neuroimaging Initiative (ADNI) data, and research from numerous international groups have all confirmed the association between plasmalogen deficiency and cognitive decline.
THERAPEUTIC IMPLICATIONS

Restoring Plasmalogens: Treatment Implications

The plasmalogen hypothesis represents more than just another theory about Alzheimer’s disease, it represents a fundamental reconceptualization based on sound biochemistry. By understanding that neuronal membranes require specific lipid compositions to function properly, and that age-related deficiency in these critical lipids creates vulnerability to neurodegeneration, we gain a coherent explanation for multiple observations about Alzheimer’s disease:

  • Why age is the strongest risk factor (peroxisomal function declines, oxidative stress increases)
  • Why ApoE4 increases risk (affects plasmalogen metabolism and cholesterol transport)
  • Why oxidative stress is prominent (plasmalogens are sacrificial antioxidants)
  • Why cholinergic deficits occur (membrane dysfunction impairs neurotransmitter release)
  • Why membrane cholesterol is elevated (plasmalogens normally regulate cholesterol)
  • Why amyloid accumulates (elevated cholesterol and altered membrane processing)

Most importantly, this understanding points toward a therapeutic approach that is now under active investigation. The journey from discovery in 2005 to early clinical investigation in 2020 to planned FDA regulatory evaluation represents the careful, systematic work necessary to translate scientific insight into a candidate therapy.

For the first time in the long struggle against Alzheimer’s disease, research is moving beyond symptom management toward addressing underlying biochemistry. The rationale for plasmalogen-targeted investigation lies in understanding — and potentially restoring — the fundamental membrane lipid composition that supports healthy brain function.

References

  1. Hugo J, Ganguli M. Dementia and cognitive impairment: epidemiology, diagnosis, and treatment. Clin Geriatr Med 2014;30:421–42. https://doi.org/10.1016/j.cger.2014.04.001
  2. Reiss D, Beyer K, Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J1997;323(Pt3):807-14. https://doi.org/10.1042/bj3230807.
  3. Han XL, Gross RW. Plasmenylcholine and phosphatidylcholine membrane bilayers possess distinct conformational motifs. Biochemistry 1990;29:4992-6.https://doi.org/10.1021/bi00472a032.
  4. Glaser PE, Gross RW. Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation. Biochemistry 1994;33:5805-12.https://doi.org/10.1021/bi00185a019.
  5. Munn NJ, et al. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res 2003;44:182-192. https://doi.org/10.1194/jlr.m200363-jlr200.
  6. Goodenowe DB, Cook LL, Liu J, Lu Y, Jayasinghe DA, Ahiahonu PW, et al. Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer’s disease and dementia. J Lipid Res 2007;48:2485–98. https://doi.org/10.1194/jlr.P700023-JLR200.
  7. Wood PL, Khan MA, Mankidy R, Smith T, Goodenowe DB. Circulating plasmalogen levels and Alzheimer Disease Assessment Scale-Cognitive scores in Alzheimer patients. J Psychiatry Neurosci 2010;35:59-62. https://pubmed.ncbi.nlm.nih.gov/20040248/.
  8. Wood PL, et al. Plasmalogen Deficit: A New and Testable Hypothesis for the Etiology of Alzheimer’s Disease. In: De La Monte S, ed. Alzheimer’s Disease Pathogenesis-Core Concepts, Shifting Paradigms and Therapeutic Targets. London, UK: InTech; 2011.https://doi.org/10.5772/17630
  9. Senanayake V, Goodenowe DB. Plasmalogen deficiency and neuropathology in Alzheimer’s disease. Alzheimer’s & Dementia: Translational Research & Clinical Interventions 2019;5:524-532. https://doi.org/10.1016/j.trci.2019.08.003.
  10. Gorgas K, et al. The Ether Lipid-Deficient Mouse: Tracking Down Plasmalogen Functions. Biochim Biophys Acta 2006;1763:1511-1526.https://doi.org/10.1016/j.bbamcr.2006.08.038.
  11. Cutler RG, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease. Proc Natl Acad Sci USA 2004;101:2070-5. https://doi.org/10.1073/pnas.0305799101.
  12. Puglielli L, et al. Alzheimer’s Disease: the Cholesterol Connection. Nat Neurosci2003;6(4):345-351. https://doi.org/10.1038/nn0403-345.
  13. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer’s disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem 2001;77:1168-80.https://doi.org/10.1046/j.1471-4159.2001.00332.x.
  14. Wurtman RJ, Blusztajn JK, Maire JC. “Autocannibalism” of choline-containing membrane phospholipids in the pathogenesis of Alzheimer’s disease-A hypothesis. Neurochem Int 1985;7:369–72. https://doi.org/10.1016/0197-0186(85)90127-5.
  15. Rothhaar TL, et al. Plasmalogens inhibit APP processing by directly affecting gamma-secretase activity in Alzheimer’s disease. Scientific World Journal 2012;2012:141240.https://doi.org/10.1100/2012/141240.
  16. Grimm MO, et al. Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer’s disease. J Neurochem 2011;116:916–25.https://doi.org/10.1111/j.1471-4159.2010.07070.x.
  17. Kou J, et al. Peroxisomal alterations in Alzheimer’s disease. Acta Neuropathol 2011;122:271–83. https://doi.org/10.1007/s00401-011-0836-9.
  18. Terlecky SR, Koepke JI, Walton PA. Peroxisomes and aging. Biochim Biophys Acta2006;1763:1749–54. https://doi.org/10.1016/j.bbamcr.2006.08.017.
  19. Jenkins CM, et al. Cytochrome c is an oxidative stress-activated plasmalogenase that cleaves plasmenylcholine and plasmenylethanolamine at the sn-1 vinyl ether linkage. J Biol Chem 2018;293:8693–709. https://doi.org/10.1074/jbc.RA117.001629.
  20. Maeba R, et al. Plasmalogens in human serum positively correlate with high-density lipoprotein and decrease with aging. J Atheroscler Thromb 2007;14:12-8.https://doi.org/10.5551/jat.14.12.
  21. Goodenowe DB, Senanayake V. Relation of Serum Plasmalogens and APOE Genotype to Cognition and Dementia in Older Persons in a Cross-Sectional Study. Brain Sci2019;9:92. https://doi.org/10.3390/brainsci9040092.
  22. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res 1995;698:223-6. https://doi.org/10.1016/0006-8993(95)00931-f.
  23. Goodenowe DB. Patent applications and presentations on plasmalogen discovery, 2005-2007.- US Patents: US9034923, https://patents.google.com/patent/US9034923. US9517222, https://patents.google.com/patent/US9517222. US10302624, https://patents.google.com/patent/US10302624.
  24. Kling MA, et al. Circulating ethanolamine plasmalogen indices in Alzheimer’s disease: Relation to diagnosis, cognition, and CSF tau. Alzheimers Dement 2020.https://doi.org/10.1002/alz.12110.
  25. Huynh K, et al. Concordant peripheral lipidome signatures in two large clinical studies of Alzheimer’s disease. Nat Commun 2020;11:5698. https://doi.org/10.1038/s41467-020-19473-7.
  26. Su XQ, Wang J, Sinclair AJ. Plasmalogens and Alzheimer’s disease: a review. Lipids Health Dis 2019;18:100. https://doi.org/10.1186/s12944-019-1044-1.
  27. Goodenowe D, Haroon J, Kling MA, et al. Targeted plasmalogen supplementation: Effects on blood plasmalogens, oxidative stress biomarkers, cognition, and mobility in cognitively impaired persons. Front Cell Dev Biol 2022;10:864842.https://doi.org/10.3389/fcell.2022.864842.
  28. Dorninger F, Forss-Petter S, Berger J. From Peroxisomal Disorders to Common Neurodegenerative Diseases – the Role of Ether Phospholipids in the Nervous System. FEBS Lett 2017;591:2761–2788. https://doi.org/10.1002/1873-3468.12788.
  29. Brites P, et al. Functions and biosynthesis of plasmalogens in health and disease. Biochim Biophys Acta 2004;1636:219–31. https://doi.org/10.1016/j.bbalip.2003.12.010.